Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJanuary 6, 2020ReblogShareTweetShareDURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mr. Kane will also participate in a panel discussion titled “Emerging Cell Therapies for Cancer” during the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapies State of the Industry Briefing.J.P. Morgan PresentationDate: Wednesday, January 15, 2020Presentation time: 11:30-11:55 a.m. PTQ&A breakout session: 12:00-12:25 p.m. PTLocation: Westin St. Francis Hotel, San Francisco Webcast link available hereFollowing the conference, a replay of the webcast will be archived for 30 days on the Precision BioSciences website.ARM Cell & Gene Therapies State of the Industry BriefingDate: Monday, January 13, 2020Time: 8:00 a.m.- 9:50 a.m. PTPanel discussion: 8:20 a.m.- 9:05 a.m. PTLocation: Parc 55 Hotel, San FranciscoAbout Precision BioSciences, Inc.Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visit www.precisionbiosciences.com.Investor Contact: Nick Riddle Precision BioSciences Tel. (919) 314-5512IR@precisionbiosciences.comMedia Contact: Cory Tromblee Scient Public Relations Tel. (617) 571-7220 cory@scientpr.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextWhy This Small Gene Therapy Player Rocketed On A Biogen DealInvestor's Business DailySarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss EstimatesZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance